2. Signaling Pathways
  3. Epigenetics
    PI3K/Akt/mTOR
  4. AMPK

AMPK

AMP-activated protein kinase

AMPK

Related Products

PDF 1.07 MB

AMPK (AMP-activated protein kinase) is an enzyme that plays a role in cellular energy homeostasis. It consists of three proteins (subunits) that together make a functional enzyme. The net effect of AMPK activation is stimulation of hepatic fatty acid oxidation andketogenesis, inhibition of cholesterol synthesis, lipogenesis, and triglyceride synthesis, inhibition of adipocyte lipolysis and lipogenesis, stimulation of skeletal muscle fatty acid oxidation and muscle glucose uptake by pancreatic beta-cells. AMPK acts as a metabolic master switch regulating several intracellular systems including the cellular uptake of glucose, the β-oxidation of fatty acids and the biogenesis of glucose transporter 4 (GLUT4) and mitochondria.

AMPK Isoform Specific Products:

AMPK Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-N2341S
    Palmitelaidic acid-d13
    		Activator 99.0%
    Palmitelaidic acid-d13 is the deuterium labeled Palmitelaidic Acid. Palmitelaidic Acid (9-trans-Hexadecenoic acid) is the trans isomer of palmitoleic acid. Palmitoleic acid is one of the most abundant fatty acids in serum and tissue.
    Palmitelaidic acid-d<sub>13</sub>
  • HY-120904
    AMPK-IN-1
    		Activator
    AMPK-IN-1 is an activator of AMPK (EC50: 551 nM for isoform α2β2γ1). AMPK-IN-1 leads to eEF2 phosphorylation in a mTORC1-independent way.
    AMPK-IN-1
  • HY-N2423
    Sinigrin hydrate
    		Activator 99.77%
    Sinigrin (Allyl-glucosinolate) hydrate is an orally active glucosinolate found in cruciferous plants. Sinigrin hydrate possesses multiple activities such as anti-cancer, antibacterial, antifungal, anti-inflammatory, antioxidant, and inhibition of fat synthesis. Sinigrin hydrate can be used in the research of tumors, inflammatory, and metabolic diseases.
    Sinigrin hydrate
  • HY-158329
    Alloc-DOX
    		Inhibitor 98.40%
    Alloc-DOX (N-Alloc doxorubicin) is a Doxorubicin (HY-15142A) prodrug. The combination of a catalyst (such as nano-palladium) and alloc-DOX leads to a decrease in cell viability and tumour growth.
    Alloc-DOX
  • HY-169652
    NPC26
    		Activator 98.0%
    NPC26 is a small molecule mitochondrial disruptor with anti-tumor activity. NPC-26 shows significant anti-proliferative and cytotoxic effects on CRC cell lines (HCT-116, DLD-1, and HT-29). NPC26 can damage mitochondrial function, leading to the opening of the mitochondrial permeability transition pore (mPTP) and the production of reactive oxygen species, ultimately inducing cell death. NPC-26 can kill CRC cells by activating the AMP-activated protein kinase (AMPK) signaling pathway.
    NPC26
  • HY-169131
    ALKBH1-IN-3 prodrug
    		Activator 99.15%
    ALKBH1-IN-4 prodrug (Compound 29E) is a prodrug of a DNA N6-methyladenine demethylase ALKBH1 inhibitor that significantly increases the abundance of 6mA in cells and upregulates the AMPK signaling pathway, thereby inhibiting the viability of gastric cancer cells. ALKBH1-IN-4 prodrug exhibits excellent cellular activity and favorable metabolic exposure in vivo, and holds promise for research in gastric cancer.
    ALKBH1-IN-3 prodrug
  • HY-N0592
    Demethyleneberberine
    		Activator ≥98.0%
    Demethyleneberberine is a natural mitochondria-targeted antioxidant. Demethyleneberberine alleviates mice colitis and inhibits the inflammatory responses by inhibiting NF-κB pathway and regulating the balance of Th cells. Demethyleneberberine could serve as a AMPK activator for treating non-alcoholic fatty liver disease (NAFLD).
    Demethyleneberberine
  • HY-136540
    Resolvin D3
    Resolvin D3 (RvD3) is a docosahexaenoic acid (DHA) derived mediator. Resolvin D3 is dysregulated in arthritis and reduces arthritic inflammation.
    Resolvin D3
  • HY-N6853
    Mogroside I E1
    		Activator 99.11%
    Mogroside I E1 is a triterpenoid glycoside and a nonsugar sweetener. Mogrosides are sweeter than sucrose. Mogrosides exhibit antioxidant, antidiabetic and anticancer activities.
    Mogroside I E1
  • HY-170360
    UCB9386
    		Inhibitor 99.89%
    UCB9386 is the selective and brain penetrant inhibitor for Nuak1 with a pIC50 of 10.1. UCB9386 inhibits Nuak2 and Kak2 with an inhibition rate of ca. 50% at 10 nM.
    UCB9386
  • HY-N6913
    3α-Hydroxymogrol
    		Activator 99.88%
    3α-Hydroxymogrol is a triterpenoid isolated from Siraitia grosvenorii Swingle, acts as a potent AMPK activator, and enhances AMPK phosphorylation.
    3α-Hydroxymogrol
  • HY-12357S2
    Bempedoic acid-d4
    		Inhibitor 98.0%
    Bempedoic acid-d4 is the deuterium labeled Bempedoic acid. Bempedoic acid (ETC-1002) is an ATP-citrate lyase (ACL) inhibitor. Bempedoic acid (ETC-1002) activates AMPK.
    Bempedoic acid-d<sub>4</sub>
  • HY-B2099
    Buformin
    		Activator
    Buformin (1-Butylbiguanide), a potent AMPK activator, acts as an orally active biguanide antidiabetic agent. Buformin decreases hepatic gluconeogenesis and lowers blood glucose production in vivo. Buformin also has anti-cancer activities and is applied in cancer study (such as, cervical cancer and breast cancer, et al).
    Buformin
  • HY-133556
    IQZ23
    		Activator
    IQZ23 inhibits adipocyte differentiation via AMPK pathway activation. IQZ23 exerts a high efficacy in decreasing the triglyceride level (EC50=0.033 μM) in 3T3-L1 adipocytes. IQZ23 could be used for the research of obesity and related metabolic disorders.
    IQZ23
  • HY-19805A
    STO-609 acetate
    		Inhibitor
    STO-609 acetate is a selective and cell-permeable inhibitor of the Ca2+/calmodulin-dependent protein kinase kinase (CaM-KK), with Ki values of 80 and 15 ng/mL for recombinant CaM-KKα and CaM-KKβ, respectively. STO-609 acetate inhibits AMP-activated protein kinase kinase (AMPKK) activity in HeLa cell lysates with an IC50 ~0.02 g/ml.
    STO-609 acetate
  • HY-B2099S
    Buformin-d9 hydrochloride
    		Activator
    Buformin-d9 (hydrochloride) is the deuterium labeled Buformin. Buformin (1-Butylbiguanide), a potent AMPK activator, acts as an orally active biguanide antidiabetic agent. Buformin decreases hepatic gluconeogenesis and lowers blood glucose production in vivo. Buformin also has anti-cancer activities and is applied in cancer study (such as, cervical cancer and breast cancer, et al).
    Buformin-d<sub>9</sub> hydrochloride
  • HY-153058
    LRRK2-IN-8
    		Inhibitor
    LRRK2-IN-8 is a LRRK2 inhibitor. LRRK2-IN-8 inhibits LRRK2 (wt) and LRRK2 (G2019) with IC50s lower than 10 nM, and inhibits TYK2 and NUAK1 with IC50s of 10-100 nM.
    LRRK2-IN-8
  • HY-119327
    Butylate
    Butylate is a compound involved in platelet research. Platelet activation can cause autophagy, which is partly mediated by the AMPK-MTOR pathway and is related to sphingolipid metabolism. Butylate mentioned in the study may be a tool or control substance for studying related metabolic processes.
    Butylate
  • HY-176297
    Tezampanel etibutil
    		Antagonist
    Tezampanel etibutil is an orally active AMPA/GluR antagonist. Tezampanel etibutil can be used in the research of pain, migraine, and neurological disorders.
    Tezampanel etibutil
  • HY-W984782
    Flindersine
    		Inducer
    Flindersine is an antidiabetic and antioxidant agent. Flindersine can result in a decline of blood glucose levels in rats. Flindersine also reduces the body weight gain, plasma insulin concentration, urea, creatinine, total cholesterol, triglycerides and free fatty acids levels in vivo. Flindersine enhances the phophotylation of GLUT4, AMPK, and PPARγ in adipose tissues and skeletal muscles.
    Flindersine
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity
AMPK Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.